Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Low back pain is a major public health problem. It is the leading cause of disability in the world. The factors that lead to chronicity of low back pain are multi-factorial and are essentially represented by psychosocial factors (catastrophism, kinesiophobia, algophobia job dissatisfaction, emotional problems such as depression, anxiety, stress, injustice, etc.).
Pain is a multimodal experience that involves different brain structures that are activated by the pain signal and involve the autonomic nervous system (ANS). The vagus nerve is the main actor of one of the two branches of the ANS, the parasympathetic system, which acts as a "slow-down".
The vagus nerve participates in the inter-neuronal transmission of key neurotransmitters for mood, alertness, attention and motivation.
Vagal stimulation has been used for many years as an analgesic device in chronic pain (vascular pain (facial vascular pain, fibromyalgia, visceral pain, gastrointestinal and pelvic pain...)
To date, no study has been conducted on the value of vagal stimulation in chronic low back pain.
Low back pain is a major public health problem. It is the leading cause of disability in the world.
The factors that lead to chronicity of low back pain are multifactorial, which explains the modest effectiveness of both drug treatments and multidisciplinary programs (analgesic drug interventions, non-pharmacological interventions with rehabilitation, physical exercise, psychotherapy, spinal ergonomics, meditation, yoga, etc.) in the treatment of low back pain. psychotherapy, spinal ergonomics, meditation, yoga...) in chronic forms. These factors of chronicization are essentially represented by psychosocial factors (catastrophism, kinesiophobia, algophobia, job dissatisfaction, emotional problems such as depression, anxiety stress, injustice...)
In the chronic low back pain population, pain is a multimodal experience that involves different brain structures (insula, anterior cingulate cortex, amygdala and prefrontal cortex). These structures are activated by the pain signal and involve the autonomic nervous system (ANS).
The vagus nerve is the main actor of one of the two branches of the ANS, the parasympathetic system, which acts as a "slow-down".
The vagus nerve is involved in the inter-neuronal transmission of key neurotransmitters for mood, alertness, attention and motivation (serotonin, dopamine, oxytocin and noradrenaline).
It is one of the longest nerves in the human body, originating from the base of the brain (nucleus tractus solitarius) and innervating most of the organs (heart, lung, stomach, liver, spleen, kidneys, gallbladder, pancreas, intestines). It allows the integration of information from the periphery (pain, stress, emotions), slows down the heart rate after a stress, reduces the caliber of the bronchial tubes to help breathing, reduces the inflammatory response, participates in digestion and in the communication with the digestive microbiota.
Indeed, there seems to be an alteration of the vagal function in chronic pain patients patients: the vagus nerve is involved in the modulation of pain at different levels (medullary, cerebral) (medullary, cerebral) but also on the different components of pain (sensory, affective emotional, behavioral).
The benefit of the stimulation of the vagus would be mediated by a modulation of afferent information (stress, pain, emotion) associated with a benefit of "relaxation" conveyed by the efferent fibers (cardiac, pulmonary effect...).
This stimulation of the vagus nerve is done through an atrial electrode that stimulates the atrial branch of the vagus nerve.
To date, no study has been conducted on the value of vagal stimulation in chronic low back pain.
Because of the multifactorial mechanisms involved in this pathology, this type of therapy appears to be a useful complement to the management of our patients.
This pilot study will allow us to evaluate the feasibility of a larger study with a placebo arm.
The evaluation of tolerance and adherence to this therapy will be taken into account.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| low back pain | Experimental | The experimental intervention consists of vagal stimulation using the Tens Eco device with an auricular electrode and conductive gel. The stimulation will have an intensity of 25 Hz, lasting 30 minutes, once a day, for 3 months. An evaluation of the pain will be done every week by phone for the first month and then in consultation at one month and at 3 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| use of an auricular electrode | Device | Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone. |
| Measure | Description | Time Frame |
|---|---|---|
| change from baseline pain at 1 month | evaluated by a Visual Analog Scale (VAS, 0 the worst result and 100 the best result) | between baseline and 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| change from baseline functional disability at 1 month | evaluated by Oswestry score The questionnaire consists of 10 questions, concerning: pain, self-care, load carrying, walking, sitting, standing, sleep, sexual life, social life, travel. Score between 0 and 20%: minimal disability Score between 21 and 40%: moderate disability Score between 41 and 60% : severe disability Score between 61 and 80% : major disability Score between 81 and 100% : bedridden patient |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Montpellier | Montpellier | France | 34295 | France | ||
| CHU Nîmes - Le Grau du Roi |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39768526 | Result | Tavares-Figueiredo I, Pers YM, Duflos C, Herman F, Sztajnzalc B, Lecoq H, Laffont I, Dupeyron AF, Homs AF. Effect of Transcutaneous Auricular Vagus Nerve Stimulation in Chronic Low Back Pain: A Pilot Study. J Clin Med. 2024 Dec 13;13(24):7601. doi: 10.3390/jcm13247601. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017116 | Low Back Pain |
| ID | Term |
|---|---|
| D001416 | Back Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Single Group Assignment
Not provided
Not provided
Not provided
Not provided
| between baseline and 1 month |
| change from baseline functional disability at 3 month | evaluated by Oswestry score The questionnaire consists of 10 questions, concerning: pain, self-care, load carrying, walking, sitting, standing, sleep, sexual life, social life, travel. Score between 0 and 20%: minimal disability Score between 21 and 40%: moderate disability Score between 41 and 60% : severe disability Score between 61 and 80% : major disability Score between 81 and 100% : bedridden patient | between baseline and 3 month |
| change from baseline quality of life at 1 month | evaluated by EQ-5D-5L score (0 to 20, 0 the better, and 20 the worst ; 0 to 100 for the L part, 0 the worst and 100 the better) | between baseline and 1 month |
| change from baseline quality of life at 3 month | evaluated by EQ-5D-5L score (0 to 20, 0 the better, and 20 the worst ; 0 to 100 for the L part, 0 the worst and 100 the better) | between baseline and 3 month |
| change from baseline anxiety and depression at 1 month | evaluated by HAD (Hospital Anxiety and Depression scale) score | between baseline and 1 month |
| change from baseline anxiety and depression at 3 month | evaluated by HAD (Hospital Anxiety and Depression scale) score | between baseline and 3 month |
| change from baseline catastrophism at 1 month | evaluated by PCS (Pain Catastrophizing Scale) score | between baseline and 1 month |
| change from baseline catastrophism at 3 month | evaluated by PCS (Pain Catastrophizing Scale) score | between baseline and 3 month |
| evolution of use of painkillers at 1 month | between baseline and 1 month |
| evolution of use of painkillers at 3 month | between baseline and 3 month |
| evaluation of device adherence at 1 month | number of stimulations performed | between baseline and 1 month |
| evaluation of device adherence at 3 month | number of stimulations performed | between baseline and 3 month |
| evaluation of device tolerance at 1 month | number of adverse events | between baseline and 1 month |
| evaluation of device tolerance at 3 month | number of adverse events | between baseline and 3 month |
| evaluation of device satisfaction at 1 month | Lickert scale from 1 to 5. | between baseline and 1 month |
| evaluation of device satisfaction at 3 month | Lickert scale from 1 to 5. | between baseline and 3 month |
| change from baseline vagal tone at 1 month | evaluated by Heart Rate variability | between baseline and 1 month |
| change from baseline vagal tone at 3 month | evaluated by Heart Rate variability | between baseline and 3 month |
| Nîmes |
| 30240 |
| France |
| D013568 |
| Pathological Conditions, Signs and Symptoms |